IMRN Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immuron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.03 |
| 52 Week High | AU$5.96 |
| 52 Week Low | AU$1.59 |
| Beta | 1.18 |
| 1 Month Change | 3.05% |
| 3 Month Change | -8.97% |
| 1 Year Change | 6.01% |
| 3 Year Change | -47.00% |
| 5 Year Change | -42.33% |
| Change since IPO | -80.63% |
Recent News & Updates
Recent updates
Immuron suspends research on COVID-19 program
Aug 19Immuron says proposed trials of antibacterial drug put on clinical hold by FDA
Jul 26Immuron to get European patent for drug composition to treat bacterial infection
Jul 07Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%
Dec 15Immuron soars 26% on positive vaccine responses in gut mediated pathogens
Nov 11Shareholder Returns
| IMRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.4% | 1.9% | 0.7% |
| 1Y | 6.0% | -6.6% | 23.9% |
Return vs Industry: IMRN exceeded the US Biotechs industry which returned -6.6% over the past year.
Return vs Market: IMRN underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| IMRN volatility | |
|---|---|
| IMRN Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMRN's weekly volatility has decreased from 27% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 7 | Steve Lydeamore | www.immuron.com.au |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Immuron Limited Fundamentals Summary
| IMRN fundamental statistics | |
|---|---|
| Market cap | US$11.25m |
| Earnings (TTM) | -US$4.31m |
| Revenue (TTM) | US$3.05m |
3.7x
P/S Ratio-2.6x
P/E RatioIs IMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMRN income statement (TTM) | |
|---|---|
| Revenue | AU$4.90m |
| Cost of Revenue | AU$1.57m |
| Gross Profit | AU$3.34m |
| Other Expenses | AU$10.27m |
| Earnings | -AU$6.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 68.06% |
| Net Profit Margin | -141.49% |
| Debt/Equity Ratio | 0% |
How did IMRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:37 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immuron Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Sally Yanchus | Litchfield Hills Research, LLC |